(Reuters) – Merck & Co’s Chief Executive Officer Robert Davis said on Thursday the company is seeking GLP-1 treatments with benefits beyond weight loss.
The drugmaker is looking for therapies aimed at providing benefits for diabetes and other disorders along with weight loss, Davis said at a conference.
Bloomberg was the first to report on the news on Thursday.
Merck’s experimental drug efinopegdutide, which is being developed as a treatment for non-alcoholic steatohepatitis (NASH), also showed a “compelling” weight-loss benefit.
(Reporting by Pratik Jain and Sriparna Roy in Bengaluru; Editing by Pooja Desai)
